IDIOPATHIC AND PROGRESSIVE PULMONARY FIBROSIS: A REVIEW OF NEW CLINICAL TRIALS
Keywords:
idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, nerandomilast
Abstract
Data from the FIBRONEER-IPF and FIBRONEER-ILD studies demonstrate the clinical efficacy of the
phosphodiesterase 4B inhibitor nerandomilast, administered alone or in combination with other antifibrotic agents, in slowing the decline in lung function in patients with idiopathic and progressive pulmonary fibrosis
How to Cite
1.
Malakauskas K. IDIOPATHIC AND PROGRESSIVE PULMONARY FIBROSIS: A REVIEW OF NEW CLINICAL TRIALS [Internet]. PIA 2025 Sep.;9(2):218-221.[cited 2025 Oct. 1 ] Available from: http://pia.pulmoalerg.lt/index.php/PIA/article/view/1750
Section
Pharmacotherapy
